Medcross Medical Center continues to expand the range of medical services it offers with the addition of new highly specialized diagnostic procedures that significantly improve the possibilities for accurate and timely urinary diagnosis of bladder cancer.

BTA TEST is a non-invasive urinary test for the qualitative detection of bladder tumor antigen. It is performed by a urologist and the results are ready in just 5 minutes.

Bladder cancer, also known as urothelial carcinoma, is the sixth most common cancer in men and the seventeenth most common in women. Unfortunately, its incidence worldwide is constantly increasing. Risk factors include smoking, a sedentary lifestyle, family history, chronic bladder infection, etc.

The gold standard in detecting, monitoring, and controlling the disease is regular cystoscopy. However, the invasive nature of this examination often causes patients to refuse to undergo it. Computed tomography (CT) scans with contrast and magnetic resonance imaging (MRI) are also established practices for diagnosing bladder cancer. Patients’ reservations about these tests are related to their high cost and radiation exposure.

It is precisely these factors, as well as the social significance of the disease, that are at the root of modern medicine’s search for alternative methods for early diagnosis, prevention, and control of such diseases.

BTA – the test for detecting tumor antigen in urine is a highly reliable and easy method for detecting primary or recurrent bladder cancer. This test does not replace or supersede cystoscopic examinations, CT scans, and magnetic resonance imaging, but it can be used as an initial diagnosis in patients who, for one reason or another, refuse to undergo them.

Source: Urology Clinic at St. Marina Hospital – Pleven, Clinical Urology, Volume 3, Issue 2/2023.